Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging

被引:223
作者
Bhasin, S
Calof, OM
Storer, TW
Lee, ML
Mazer, NA
Jasuja, R
Montori, VM
Gao, WQ
Dalton, JT
机构
[1] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA
[2] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA
[4] Mayo Clin, Rochester, MN USA
[5] Ohio State Univ, Columbus, OH 43210 USA
来源
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2006年 / 2卷 / 03期
关键词
anabolic therapies; androgens; sarcopenia; selective androgen receptor modulators; testosterone;
D O I
10.1038/ncpendmet0120
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with beta-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.
引用
收藏
页码:146 / 159
页数:14
相关论文
共 88 条
  • [81] EFFECTS OF TESTOSTERONE SUPPLEMENTATION IN THE AGING MALE
    TENOVER, JS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (04) : 1092 - 1098
  • [82] Three-dimensional quantitative structure-activity relationships for androgen receptor ligands
    Waller, CL
    Juma, BW
    Gray, LE
    Kelce, WR
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1996, 137 (02) : 219 - 227
  • [83] Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men - A clinical research center study
    Wang, C
    Eyre, DR
    Clark, R
    Kleinberg, D
    Newman, C
    Iranmanesh, A
    Veldhuis, J
    Dudley, RE
    Berman, N
    Davidson, T
    Barstow, TJ
    Sinow, R
    Alexander, G
    Swerdloff, RS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) : 3654 - 3662
  • [84] Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men
    Wang, C
    Swerdloff, RS
    Iranmanesh, A
    Dobs, A
    Snyder, PJ
    Cunningham, G
    Matsumoto, AM
    Weber, T
    Berman, N
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) : 2839 - 2853
  • [85] Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men
    Wang, C
    Cunningham, G
    Dobs, A
    Iranmanesh, A
    Matsumoto, AM
    Snyder, PJ
    Weber, T
    Berman, N
    Hull, L
    Swerdloff, RS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) : 2085 - 2098
  • [86] Wittert GA, 2003, J GERONTOL A-BIOL, V58, P618
  • [87] Development of models to predict anabolic response to testosterone administration in healthy young men
    Woodhouse, LJ
    Reisz-Porszasz, S
    Javanbakht, M
    Storer, TW
    Lee, M
    Zerounian, H
    Bhasin, S
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (05): : E1009 - E1017
  • [88] Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor
    Yin, DH
    He, YL
    Perera, MA
    Hong, SS
    Marhefka, C
    Stourman, N
    Krikovsky, L
    Miller, DD
    Dalton, JT
    [J]. MOLECULAR PHARMACOLOGY, 2003, 63 (01) : 211 - 223